Results 81 to 90 of about 5,784 (166)

Antagonizing the hedgehog pathway with vismodegib impairs malignant pleural mesothelioma growth in vivo by affecting stroma [PDF]

, 2016
An autocrine driven upregulation of the Hedgehog (Hh) signaling pathway has been described in malignant pleural mesothelioma (MPM), in which the ligand, desert hedgehog (DHH), was produced from tumor cells. However, our investigation revealed that the Hh
Arni, Stephan, Meerang, Mayura, Felley-Bosco, Emanuela, Stahel, Rolf A, Weder, Walter, Broggini-Tenzer, Angela, Bérard, Karima, Vrugt, Bart, Boss, Andreas, Kenkel, David, Lauk, Olivia, Opitz, Isabelle, Boss, A., Opitz, I., Stahel RA, Felley-Bosco E, Vrugt, B., Weder W, Meerang M, Kenkel D, Arni S, Boss A, Bérard K, Opitz I, Broggini-Tenzer A, Felley-Bosco, E., Kenkel, D., Bérard, K., Lauk O, Vrugt B, Lauk, O., Broggini-Tenzer, A., Meerang, M., Weder, W., Stahel, R.A., Arni, S.   +35 more
core   +1 more source

Adverse events associated with vismodegib: insights from a real-world pharmacovigilance study using the FAERS database

Frontiers in Pharmacology
BackgroundVismodegib, an inhibitor of the Hedgehog signaling pathway, has been widely used in the treatment of advanced basal cell carcinoma. Given its critical role in managing advanced basal cell carcinoma and the relatively high rate of treatment ...
Bingqing Wang, Kaidi Zhao, Ningyi Xian, Landong Ren, Jiashu Liu, Chen Tu, Dewu Zhang   +6 more
doaj   +1 more source

Vismodegib: A smoothened inhibitor for the treatment of advanced basal cell carcinoma

Indian Dermatology Online Journal, 2013
Incidence of basal cell carcinoma (BCC), the most common skin cancer in humans, is rising. Surgery is the mainstay of treatment but there is no standard of care for locally advanced or metastatic disease. Hedgehog signaling proteins are critical for cell
Suruchi Aditya, Aditya Rattan
doaj   +1 more source

A case illustrating successful eradication of recurrent, aggressive basal cell carcinoma located in a scar with vismodegib [PDF]

, 2018
Vismodegib is a small molecule inhibitor of the Hedgehog signaling pathway that has shown efficacy in the control of locally advanced or metastatic basal cell carcinoma, although proof of its effectiveness in the elimination of aggressive tumors is ...
Lucero, Olivia M, Leitenberge, Justin, Thompson, Curtis, Fitzmaurice, Sarah, Justin Leitenberge, Curtis Thompson, Lucero, Olivia M ; Fitzmaurice, Sarah ; Thompson, Curtis ; Leitenberge, Justin, Olivia M Lucero, Sarah Fitzmaurice   +8 more
core   +1 more source

Spotlight on vismodegib in the treatment of basal cell carcinoma: an evidence-based review of its place in therapy

, 2017
Zoe Apalla,1 Chrysoula Papageorgiou,1 Aimilios Lallas,1 Elena Sotiriou,1 Elizabeth Lazaridou,1 Efstratios Vakirlis,1 Athanassios Kyrgidis,2 Demetrios Ioannides1 1First Department of Dermatology, Aristotle University, 2Department of Oral and Maxillofacial
Ioannides D, Vakirlis E, Sotiriou E, Papageorgiou C, Lallas A, Apalla Z, Kyrgidis A, Lazaridou E   +7 more
core  

PHARMACEUTICAL COMPOSITION OF VISMODEGIB CAPSULES 150 mg [PDF]

A stabilized pharmaceutical composition comprising Vismodegib or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said composition simultaneously achieves desired dissolution profile, stability ...
Anonymous,
core   +2 more sources

Upfront Radiotherapy with Concurrent and Adjuvant Vismodegib Is Effective and Well-Tolerated in a Patient with Advanced, Multifocal Basal Cell Carcinoma

Case Reports in Dermatological Medicine, 2018
We present a case report of a male with multifocal and extensive basal cell carcinoma. Due to extremely large size and deep tumor infiltration, he was not a surgical candidate.
Abigail I. Franco, Gary Eastwick, Ramsay Farah, Marvin Heyboer, Mijung Lee, Paul Aridgides   +5 more
doaj   +1 more source

Vismodegib beim lokal fortgeschrittenen Basalzellkarzinom des Mittelgesichts

, 2015
Einleitung: Das Basalzellkarzinom im fortgeschrittenen Stadium kann in Knochen und in Sinnesorgane eindringen, je nach Lokalisation stark entstellend und lebensbedrohlich sein. Vismodegib ist ein Hedgehog-Signalweg-Inhibitor.
Wang, J, Laubert, A, Eichhorn, S
core   +1 more source

Survey of the impact of BOLT-trial data on oncologists’ and dermatologists’ decision-making in treating patients with locally advanced basal cell carcinoma

Dermatology Reports
Basal cell carcinoma (BCC) is the most common malignant tumour in white populations. Multiple studies demonstrated that the aberrant activation of Hedgehog signaling is a driver of BCC development, and its blockade represents a potential therapeutic ...
Luigi Scarpato, Marco Palla, Sabino Strippoli, Luca Tagliaferri, Luca Fania, Maristella Saponara, Anna Carbone, Francesco Spagnolo, Flavia Silvestri, Paolo Antonio Ascierto   +9 more
doaj   +1 more source

Vismodegib, a small-molecule inhibitor of the Hedgehog pathway for the treatment of advanced cancers

, 2010
Vismodegib (GDC-0449) is a small, orally administrable molecule, belonging to the 2-arylpyridine class, which was discovered by Genentech Inc under a collaboration with Curis Inc.
FERRETTI, ELISABETTA, DE SMAELE, Enrico, GULINO, Alberto   +2 more
core